HRP20140116T1 - Derivati retinala i postupci za njihovu upotrebu u lijeäśenju poremeä†aja vida - Google Patents

Derivati retinala i postupci za njihovu upotrebu u lijeäśenju poremeä†aja vida Download PDF

Info

Publication number
HRP20140116T1
HRP20140116T1 HRP20140116TT HRP20140116T HRP20140116T1 HR P20140116 T1 HRP20140116 T1 HR P20140116T1 HR P20140116T T HRP20140116T T HR P20140116TT HR P20140116 T HRP20140116 T HR P20140116T HR P20140116 T1 HRP20140116 T1 HR P20140116T1
Authority
HR
Croatia
Prior art keywords
cis
retinal
retinyl
human subject
treatment
Prior art date
Application number
HRP20140116TT
Other languages
English (en)
Croatian (hr)
Inventor
Krzysztof Palczewski
Matthew Batten
Original Assignee
University Of Washington , Intellectual Property And Technology Transfer, 4311
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Washington , Intellectual Property And Technology Transfer, 4311 filed Critical University Of Washington , Intellectual Property And Technology Transfer, 4311
Publication of HRP20140116T1 publication Critical patent/HRP20140116T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
    • C07C403/10—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by etherified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
    • C07C403/12—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/14—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HRP20140116TT 2004-06-18 2005-06-20 Derivati retinala i postupci za njihovu upotrebu u lijeäśenju poremeä†aja vida HRP20140116T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58088904P 2004-06-18 2004-06-18
PCT/US2005/021812 WO2006002097A2 (en) 2004-06-18 2005-06-20 Retinal derivatives and methods for the use thereof for the treatment of visual disorders

Publications (1)

Publication Number Publication Date
HRP20140116T1 true HRP20140116T1 (hr) 2014-03-28

Family

ID=35782277

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140116TT HRP20140116T1 (hr) 2004-06-18 2005-06-20 Derivati retinala i postupci za njihovu upotrebu u lijeäśenju poremeä†aja vida

Country Status (26)

Country Link
US (8) US7951841B2 (cg-RX-API-DMAC7.html)
EP (5) EP1765322B1 (cg-RX-API-DMAC7.html)
JP (2) JP5166026B2 (cg-RX-API-DMAC7.html)
KR (4) KR101490145B1 (cg-RX-API-DMAC7.html)
CN (2) CN1988898B (cg-RX-API-DMAC7.html)
AU (1) AU2005257997B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0511396B1 (cg-RX-API-DMAC7.html)
CA (2) CA2571049C (cg-RX-API-DMAC7.html)
CY (2) CY1114873T1 (cg-RX-API-DMAC7.html)
DK (2) DK2397133T3 (cg-RX-API-DMAC7.html)
ES (4) ES2644981T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20140116T1 (cg-RX-API-DMAC7.html)
HU (1) HUE036596T2 (cg-RX-API-DMAC7.html)
IL (4) IL180078A (cg-RX-API-DMAC7.html)
IN (1) IN2012DN09335A (cg-RX-API-DMAC7.html)
LT (1) LT2397133T (cg-RX-API-DMAC7.html)
MX (2) MXPA06014750A (cg-RX-API-DMAC7.html)
NO (1) NO339969B1 (cg-RX-API-DMAC7.html)
NZ (2) NZ552080A (cg-RX-API-DMAC7.html)
PL (2) PL1765322T3 (cg-RX-API-DMAC7.html)
PT (2) PT1765322E (cg-RX-API-DMAC7.html)
RS (1) RS53178B (cg-RX-API-DMAC7.html)
RU (2) RU2408578C2 (cg-RX-API-DMAC7.html)
SI (2) SI1765322T1 (cg-RX-API-DMAC7.html)
WO (1) WO2006002097A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200700368B (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2327401A3 (en) * 2003-03-14 2011-10-19 University of Washington Retinoid Replacements and Opsin Agonists and Methods for the Use Thereof
PT1765322E (pt) 2004-06-18 2014-02-05 Univ Washington Derivados de retinal e métodos para sua utilização para o tratamento de distúrbios visuais
WO2006007314A1 (en) 2004-06-23 2006-01-19 Sirion Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions with retinyl derivatives
KR100890410B1 (ko) * 2004-12-08 2009-03-26 시리온 테라퓨틱스, 인크. 레티놀-관련 질환의 치료 방법, 검정법 및 치료용 조성물
WO2008013984A2 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Compositions and methods for treating or preventing ophthalmic disease
AU2007277032A1 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Opsin stabilizing compounds and methods of use
US8338394B2 (en) * 2006-10-12 2012-12-25 Case Western Reserve University Methods for treating metabolic diseases
CN101686665B (zh) 2007-04-20 2014-04-23 奥克塞拉有限公司 用于治疗眼科疾病和紊乱的苯乙烯基衍生化合物
AU2015200520B2 (en) * 2008-02-11 2017-02-09 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction
CN101969938A (zh) * 2008-02-11 2011-02-09 华盛顿大学 治疗和预防年龄相关视网膜功能障碍的方法
JP5443470B2 (ja) * 2008-04-29 2014-03-19 株式会社日健総本社 眼障害の治療方法
IN2012DN00352A (cg-RX-API-DMAC7.html) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
KR101710505B1 (ko) * 2009-09-15 2017-02-27 노벨리언 테라퓨틱스 인코포레이티드 리피드 비히클에 9-시스-레티닐 에스테르를 포함하는 약제 처방
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
US8889660B2 (en) 2010-01-20 2014-11-18 Case Western Reserve University Methods for treating obesity or an obesity related condition
CN107308143A (zh) * 2010-04-19 2017-11-03 诺维利昂治疗股份有限公司 用于治疗或改善与内源性类视黄醇缺乏有关的视觉障碍的治疗方案和方法
AU2011323237B2 (en) * 2010-11-05 2015-11-12 The Board Of Trustees Of The Leland Stanford Junior University Optically-controlled CNS dysfunction
WO2013082149A1 (en) * 2011-11-28 2013-06-06 Case Western Reserve University Polysaccharide therapeutic conjugates
RU2635536C2 (ru) * 2012-03-01 2017-11-13 Новелион Терапьютикс Инк. Схемы лечения и способы улучшения зрительной функции при расстройствах зрения, связанных с дефицитом эндогенного ретиноида
US20150038582A1 (en) * 2012-03-01 2015-02-05 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
WO2013185055A1 (en) 2012-06-07 2013-12-12 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of pin1
US20150119388A1 (en) * 2012-06-15 2015-04-30 The Children's Hospital Philadelphia Novel pro- and codrug derivatives for nanoparticle delivery of select anticancer agents formed using rapidly cleavable phenolic ester bridges
WO2015184453A1 (en) 2014-05-30 2015-12-03 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
US11129845B2 (en) 2014-06-18 2021-09-28 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
WO2016011265A2 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Biomarkers for pin1-associated disorders
US10925980B2 (en) 2014-08-04 2021-02-23 Case Western Reserve University Molecular probes and methods of use
US10548864B2 (en) 2015-03-12 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
US11407786B2 (en) 2015-06-18 2022-08-09 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US12060318B2 (en) 2015-10-09 2024-08-13 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
CA3022386A1 (en) * 2016-04-28 2017-11-02 Spark Therapeutics, Inc. Relative potency assay for viral vector encoding isomerohydrolases
CN118922182A (zh) * 2022-02-04 2024-11-08 纽约大学 类维生素a治疗心房颤动的用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB797977A (en) * 1956-01-16 1958-07-09 Hoffmann La Roche Vitamin-a esters and a process for the manufacture thereof
US3196048A (en) 1961-12-19 1965-07-20 Exxon Research Engineering Co Cathode catalyst for fuel cells
US3196078A (en) 1962-01-30 1965-07-20 Ortho Pharma Corp Process for combating retinits pigmentosa
US3517067A (en) 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
DE2300107C2 (de) * 1973-01-03 1982-03-11 Basf Ag, 6700 Ludwigshafen Vitamin A-Säureanilid-4-carbonsäureäthylester, Verfahren zu seiner Herstellung und diesen enthaltende Zubereitungen
DE2456959A1 (de) * 1974-12-03 1976-06-16 Basf Ag 4-(e)- und 4-(z)-7-methyl-9-(2,6,6trimethyl-1-cyclohexen-1-yl)-nona-2,4,6,8tetraencarbonsaeure, ihre derivate und diese enthaltende zubereitungen
JPS61275266A (ja) 1985-05-28 1986-12-05 Taisho Pharmaceut Co Ltd レチノイド誘導体
US5310764A (en) 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
JPH06340525A (ja) 1993-06-02 1994-12-13 Lion Corp 安定な低眼刺激性ビタミンａ類可溶化点眼剤
JPH09511507A (ja) 1994-04-04 1997-11-18 フリーマン，ウイリアム・アール 上昇した眼圧を治療するためのホスホニルメトキシアルキルヌクレオシドの使用
RU2106843C1 (ru) * 1994-06-29 1998-03-20 Красноярская государственная медицинская академия Способ лечения близорукости
JPH08198746A (ja) * 1995-01-18 1996-08-06 Lion Corp 可溶化点眼剤
US5837728A (en) 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US5489611A (en) 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
KR19980703668A (ko) * 1995-04-03 1998-12-05 콜비 안드라 엘 레티노이드와 리포좀을 함유하는 피부 보호용 조성물
US5620970A (en) * 1995-06-05 1997-04-15 Alcon Laboratories, Inc. Topical ophthalmic carbonic anhydrase inhibitor formulations
US5716627A (en) * 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
EP0908179A1 (en) * 1997-08-23 1999-04-14 Werner Bollag Treatment of cell-mediated immune diseases
US6391924B1 (en) 1997-12-10 2002-05-21 Hampar Karageozian Taurine derivatives useable in the treatment of ophthalmic disorders
US6552009B2 (en) 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US6372463B1 (en) 1999-05-06 2002-04-16 The President & Fellows Of Harvard College Mutations in nucleic acid molecules encoding 11-CIS retinol dehydrogenase, the mutated proteins, and uses thereof
US6300328B1 (en) 1999-08-06 2001-10-09 Alcon Universal Ltd. Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage
DE60130872T2 (de) 2000-03-10 2008-07-17 Insite Vision, Inc., Alameda Verfahren und mittel zur behandlung und vorbeugung von erkrankungen der hinteren augenkammer
US20020028849A1 (en) 2000-04-18 2002-03-07 Godkin James D. Use of retinol in assisted-reproduction protocols
US6696069B2 (en) 2000-06-30 2004-02-24 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Skin care cosmetic compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof
US7030265B2 (en) * 2001-01-11 2006-04-18 Chebigen, Inc. Retinol derivatives, the method of preparations and the uses thereof
WO2002058586A2 (en) 2001-01-26 2002-08-01 Steven Baranowitz Systemic formulations containing beta-carotene and derivatives thereof
GB0103998D0 (en) 2001-02-19 2001-04-04 King S College London Method
EP1381276A4 (en) 2001-04-13 2005-02-02 Univ Pennsylvania METHOD FOR TREATMENT OR DEVELOPMENT SLUDGE DEGRADATION
JP2005524626A (ja) * 2002-01-18 2005-08-18 タットン テクノロジーズ エルエルシー． 眼疾患を治療するための方法
US20030215413A1 (en) 2002-03-22 2003-11-20 L'oreal Compositions containing stabilized retinoid
US20040097587A1 (en) 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
CA2480047A1 (en) 2002-03-29 2003-10-09 Maxim Pharmaceuticals, Inc. Use of rom production and release inhibitors to treat and prevent intraocular damage
EP2327401A3 (en) 2003-03-14 2011-10-19 University of Washington Retinoid Replacements and Opsin Agonists and Methods for the Use Thereof
US7566808B2 (en) * 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
WO2005079774A2 (en) 2004-02-17 2005-09-01 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
AU2005221283C1 (en) 2004-03-17 2011-02-03 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
PT1765322E (pt) 2004-06-18 2014-02-05 Univ Washington Derivados de retinal e métodos para sua utilização para o tratamento de distúrbios visuais
WO2006007314A1 (en) 2004-06-23 2006-01-19 Sirion Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions with retinyl derivatives
WO2006033734A2 (en) 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
WO2006039551A2 (en) 2004-09-30 2006-04-13 The Regents Of The University Of California Local administration of retinoids to treat deficiencies in dark adaptation
PL2187880T3 (pl) 2007-09-12 2014-05-30 Univ Columbia Kompozycje i sposoby do leczenia zwyrodnienia plamki żółtej
CN101969938A (zh) 2008-02-11 2011-02-09 华盛顿大学 治疗和预防年龄相关视网膜功能障碍的方法

Also Published As

Publication number Publication date
EP2397130B1 (en) 2019-04-03
EP2397130A2 (en) 2011-12-21
US7951841B2 (en) 2011-05-31
IL180078A (en) 2014-01-30
US9388130B2 (en) 2016-07-12
US20130072559A1 (en) 2013-03-21
CN1988898B (zh) 2012-12-26
ES2752924T3 (es) 2020-04-06
HK1098696A1 (en) 2007-07-27
EP2397131A3 (en) 2012-10-31
US9403765B2 (en) 2016-08-02
IL230242A (en) 2015-10-29
CA2571049A1 (en) 2006-01-05
CY1119480T1 (el) 2018-03-07
HUE036596T2 (hu) 2018-07-30
EP2397133A3 (en) 2012-07-11
BRPI0511396A (pt) 2007-12-04
RU2408578C2 (ru) 2011-01-10
PT2397133T (pt) 2017-10-23
PL1765322T3 (pl) 2014-04-30
US20190167626A1 (en) 2019-06-06
US9174936B2 (en) 2015-11-03
ZA200700368B (en) 2008-10-29
EP2397133A2 (en) 2011-12-21
IL222347A (en) 2017-08-31
DK2397133T3 (en) 2017-10-30
EP2397132B1 (en) 2017-07-26
CY1114873T1 (el) 2016-12-14
IN2012DN09335A (cg-RX-API-DMAC7.html) 2015-08-21
US10117845B2 (en) 2018-11-06
KR101490145B1 (ko) 2015-02-05
NZ587006A (en) 2011-12-22
PL2397133T3 (pl) 2018-01-31
CN102976937A (zh) 2013-03-20
ES2644981T3 (es) 2017-12-01
EP2397131A2 (en) 2011-12-21
US9162978B2 (en) 2015-10-20
WO2006002097A2 (en) 2006-01-05
RU2554003C2 (ru) 2015-06-20
NO339969B1 (no) 2017-02-20
JP5166026B2 (ja) 2013-03-21
DK1765322T3 (da) 2014-02-10
MX359668B (es) 2018-10-05
MXPA06014750A (es) 2007-03-21
US9169204B2 (en) 2015-10-27
CN102976937B (zh) 2016-12-21
EP1765322B1 (en) 2013-11-06
US20110288170A1 (en) 2011-11-24
US20130072560A1 (en) 2013-03-21
NZ552080A (en) 2011-03-31
ES2644984T3 (es) 2017-12-01
ES2443194T3 (es) 2014-02-18
RU2007101735A (ru) 2008-07-27
RS53178B (sr) 2014-06-30
RU2010138410A (ru) 2012-03-27
WO2006002097A3 (en) 2006-05-04
KR101337321B1 (ko) 2013-12-06
KR20120062946A (ko) 2012-06-14
EP2397133B1 (en) 2017-07-26
EP2397131B1 (en) 2019-09-11
KR20140140616A (ko) 2014-12-09
IL230241A (en) 2015-06-30
PT1765322E (pt) 2014-02-05
SI1765322T1 (sl) 2014-03-31
US20080221208A1 (en) 2008-09-11
EP2397132A2 (en) 2011-12-21
JP2012229234A (ja) 2012-11-22
US20130079403A1 (en) 2013-03-28
KR101323122B1 (ko) 2013-10-30
LT2397133T (lt) 2018-01-10
KR20130079669A (ko) 2013-07-10
CA2931917A1 (en) 2006-01-05
AU2005257997B2 (en) 2012-04-05
AU2005257997A1 (en) 2006-01-05
KR20070026817A (ko) 2007-03-08
US20170014368A1 (en) 2017-01-19
EP1765322A4 (en) 2008-09-17
CN1988898A (zh) 2007-06-27
JP2008503496A (ja) 2008-02-07
EP2397130A3 (en) 2012-10-31
JP5596749B2 (ja) 2014-09-24
US20130072556A1 (en) 2013-03-21
IL180078A0 (en) 2007-05-15
BRPI0511396B1 (pt) 2021-07-27
EP2397132A3 (en) 2012-07-11
NO20070330L (no) 2007-03-15
CA2571049C (en) 2016-08-09
EP1765322A2 (en) 2007-03-28
SI2397133T1 (sl) 2017-12-29

Similar Documents

Publication Publication Date Title
HRP20140116T1 (hr) Derivati retinala i postupci za njihovu upotrebu u lijeäśenju poremeä†aja vida
USRE50218E1 (en) Non-steroidal anti-inflammatory ophthalmic compositions
JP6856275B2 (ja) 近視予防、治療又は抑制用点眼剤
CN101888839B (zh) 治疗眼睛病症的omega-3脂肪酸、羟基多不饱和脂肪酸、脂氧素类化合物或脂氧化物类化合物
AU2016298951B2 (en) Compositions for the treatment of cataracts
JPWO2006022291A1 (ja) ドライアイ治療用点眼液
WO2010048788A1 (zh) 氟比洛芬酯眼用纳米乳-原位凝胶制剂及其制备方法
US20230321023A1 (en) Application of regulation of eye sclera lipid metabolism to inhibit myopia
EP4324463A1 (en) Method and pharmaceutical composition for treating myopia
RU2015154741A (ru) Ингибитор хориоретинальных нарушений
JPH10167963A (ja) 低級アルカノイルｌ−カルニチンを含有する網膜症治療用製剤
CN116478239A (zh) 一种抗干眼症的活性肽及其应用
JP2019070026A (ja) 外用剤
JPWO2016170959A1 (ja) 粘膜免疫賦活剤
WO2015023902A2 (en) Therapeutic regimens and methods for improving visual function in visual disorders associated with impaired dark adaptation and/or impaired low luminance vision
JPWO2006098292A1 (ja) 眼疾患治療剤
CN111050777A (zh) 提供改善的眼睛舒适度的组合物
CN202740213U (zh) 一种泪道栓子
NZ782902B2 (en) Oxymetazoline compositions and methods for treating ocular disorders
RU2021135524A (ru) Композиции оксиметазолина и способы для лечения офтальмологических расстройств
Kruglova et al. Peculiarities of the surgical treatment of congenital cataracts with the use of intraocular lens implantation in the patients presenting with congenital malformations of the posterior lens capsule
Kleis et al. Caine or intravenous administration of chlorpromazine.(16 references)